Index RUT P/E - EPS (ttm) -3.60 Insider Own 4.36% Shs Outstand 57.56M Perf Week 2.99%
Market Cap 1.85B Forward P/E - EPS next Y -2.67 Insider Trans -0.57% Shs Float 55.30M Perf Month -3.99%
Income -205.80M PEG - EPS next Q -0.77 Inst Own 114.05% Short Float 22.16% Perf Quarter -3.76%
Sales 262.36M P/S 7.05 EPS this Y 14.54% Inst Trans 2.38% Short Ratio 13.76 Perf Half Y 103.11%
Book/sh 10.21 P/B 3.13 EPS next Y 13.33% ROA -25.06% Short Interest 12.25M Perf Year 178.59%
Cash/sh 5.38 P/C 5.95 EPS next 5Y - ROE -30.80% 52W Range 11.46 - 43.21 Perf YTD -13.16%
Dividend Est. - P/FCF - EPS past 5Y -6.09% ROI -30.85% 52W High -25.92% Beta 1.72
Dividend TTM - Quick Ratio 5.51 Sales past 5Y 60.13% Gross Margin 35.79% 52W Low 179.32% ATR (14) 1.78
Dividend Ex-Date - Current Ratio 5.98 EPS Y/Y TTM 6.63% Oper. Margin -78.18% RSI (14) 50.62 Volatility 5.78% 5.33%
Employees 919 Debt/Eq 0.16 Sales Y/Y TTM 21.58% Profit Margin -78.44% Recom 1.80 Target Price 40.25
Option/Short Yes / Yes LT Debt/Eq 0.13 EPS Q/Q -0.94% Payout - Rel Volume 1.26 Prev Close 31.96
Sales Surprise 6.51% EPS Surprise 3.15% Sales Q/Q 31.81% Earnings May 02 AMC Avg Volume 890.76K Price 32.01
SMA20 3.46% SMA50 -6.36% SMA200 15.40% Trades
Volume 1,118,494 Change 0.16%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-17-24 Upgrade Goldman
Neutral → Buy
$25 → $45
Sep-27-23 Initiated Berenberg
Buy
$27
Jan-05-23 Initiated Scotiabank
Sector Outperform
$33
Jan-03-23 Upgrade Evercore ISI
In-line → Outperform
$28 → $36
Mar-02-22 Resumed Cowen
Outperform
Oct-15-21 Resumed Cowen
Outperform
Jun-29-21 Initiated William Blair
Outperform
Jun-04-21 Initiated Goldman
Neutral
$110
Apr-12-21 Initiated Piper Sandler
Overweight
$150
Feb-05-21 Downgrade JP Morgan
Neutral → Underweight
$100
Jan-04-21 Downgrade Evercore ISI
Outperform → In-line
Oct-20-20 Initiated SVB Leerink
Mkt Perform
$90
May-31-19 Initiated Evercore ISI
Outperform
Nov-26-18 Initiated JP Morgan
Neutral
$27
Show Previous Ratings
May-02-24 09:00PM
05:35PM
04:33PM
(Associated Press Finance)
04:05PM
Apr-30-24 03:20PM
11:31AM
Loading…
Apr-25-24 11:31AM
Apr-18-24 08:00AM
Mar-28-24 08:00AM
Mar-05-24 08:00AM
Feb-22-24 08:00AM
Feb-13-24 01:59PM
Feb-10-24 05:28AM
Feb-07-24 08:00AM
Feb-06-24 08:05AM
08:00AM
08:09AM
Loading…
Feb-05-24 08:09AM
08:00AM
Feb-02-24 11:42PM
(Thomson Reuters StreetEvents) +10.01%
07:55AM
07:36AM
(Associated Press Finance)
07:30AM
Jan-24-24 08:00AM
Jan-16-24 08:00AM
Jan-08-24 08:00AM
Jan-05-24 08:00AM
Dec-19-23 12:44PM
Dec-18-23 08:00AM
Dec-15-23 08:11AM
Nov-20-23 08:55AM
Nov-18-23 01:29AM
(Thomson Reuters StreetEvents)
04:03PM
Loading…
Nov-17-23 04:03PM
(Investor's Business Daily) +25.90%
08:40AM
08:28AM
07:47AM
(Associated Press Finance)
07:30AM
Nov-14-23 08:00AM
Nov-13-23 08:00AM
Nov-08-23 08:00AM
Nov-02-23 04:05PM
Oct-31-23 08:00AM
Oct-16-23 10:43AM
Oct-06-23 12:08PM
11:44AM
Oct-05-23 08:00AM
Oct-03-23 08:00AM
Sep-27-23 08:00AM
Sep-26-23 01:02PM
12:40PM
Sep-20-23 12:11PM
Sep-14-23 12:56PM
12:31PM
Sep-05-23 08:00AM
Aug-31-23 03:10AM
03:00AM
Aug-22-23 08:00AM
Aug-11-23 01:39PM
Aug-07-23 09:53AM
08:00AM
Aug-04-23 01:21PM
08:45AM
07:37AM
07:30AM
Jul-20-23 08:00AM
Jul-18-23 09:50AM
08:00AM
Jun-26-23 08:10AM
Jun-20-23 08:00AM
Jun-04-23 09:46AM
May-31-23 08:00AM
May-24-23 08:00AM
May-23-23 08:00AM
May-22-23 08:00AM
May-14-23 04:05PM
May-10-23 08:00AM
May-08-23 08:54AM
May-07-23 01:18PM
May-05-23 11:02AM
08:45AM
07:30AM
May-03-23 08:45AM
May-02-23 05:53AM
Apr-28-23 10:00AM
Apr-27-23 08:00AM
Apr-26-23 02:10PM
Apr-25-23 10:00AM
06:35AM
Apr-20-23 06:24PM
08:00AM
Apr-13-23 08:00AM
07:59AM
Mar-29-23 04:20PM
08:00AM
Mar-28-23 08:03AM
(Simply Wall St.) -10.32%
Mar-09-23 08:00AM
Feb-28-23 08:00AM
Feb-20-23 09:55AM
Feb-17-23 11:08AM
Feb-14-23 08:00AM
Feb-08-23 12:00PM
09:55AM
Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Finn Patrick John President and COO Apr 23 '24 Sale 30.12 2,174 65,483 176,206 Apr 25 04:05 PM Laponis Adam Chief Financial Officer Apr 09 '24 Sale 33.16 556 18,434 74,444 Apr 11 04:05 PM Leproust Emily M. Chief Executive Officer Apr 02 '24 Sale 32.74 1,132 37,057 514,149 Apr 04 04:05 PM Finn Patrick John President and COO Apr 02 '24 Sale 32.74 492 16,106 178,380 Apr 04 04:05 PM Banyai William See Remark Apr 02 '24 Sale 32.74 327 10,705 345,986 Apr 04 04:05 PM Green Paula SVP of Human Resources Apr 02 '24 Sale 32.74 229 7,497 92,421 Apr 04 04:05 PM Cho Dennis See Remarks Apr 02 '24 Sale 32.74 129 4,223 81,004 Apr 04 04:05 PM Leproust Emily M. Chief Executive Officer Mar 20 '24 Sale 33.52 1,128 37,806 515,281 Mar 22 04:05 PM Banyai William See Remark Mar 20 '24 Sale 33.52 442 14,814 346,313 Mar 22 04:05 PM Cho Dennis See Remarks Mar 20 '24 Sale 33.52 230 7,709 81,133 Mar 22 04:05 PM Green Paula SVP of Human Resources Mar 20 '24 Sale 33.52 200 6,703 92,650 Mar 22 04:05 PM Cho Dennis See Remarks Mar 14 '24 Sale 34.60 93 3,218 81,363 Mar 18 04:05 PM Leproust Emily M. Chief Executive Officer Mar 06 '24 Sale 37.43 1,487 55,658 516,409 Mar 08 04:05 PM Green Paula SVP of Human Resources Mar 06 '24 Sale 37.43 600 22,458 92,850 Mar 08 04:05 PM Banyai William See Remark Mar 06 '24 Sale 37.43 549 20,549 346,755 Mar 08 04:05 PM Cho Dennis See Remarks Mar 06 '24 Sale 37.43 272 10,181 81,456 Mar 08 04:05 PM WERNER ROBERT F. Chief Accounting Officer Mar 06 '24 Sale 37.43 181 6,775 43,680 Mar 08 04:05 PM CHESS ROBERT Director Feb 08 '24 Sale 34.98 4,110 143,784 64,169 Feb 09 04:10 PM THORBURN JAMES M Chief Financial Officer May 23 '23 Option Exercise 11.59 13,324 154,425 62,042 May 25 04:05 PM Cho Dennis See Remarks May 10 '23 Buy 13.20 10,000 132,000 29,297 May 12 04:05 PM Leproust Emily M. Chief Executive Officer May 04 '23 Option Exercise 5.95 24,360 144,942 256,094 May 08 04:00 PM
Index - P/E - EPS (ttm) -1.46 Insider Own 3.09% Shs Outstand 191.38M Perf Week 26.52%
Market Cap 306.65M Forward P/E - EPS next Y -0.71 Insider Trans -1.28% Shs Float 177.94M Perf Month 60.58%
Income -276.06M PEG - EPS next Q -0.19 Inst Own 64.65% Short Float 1.75% Perf Quarter 187.93%
Sales 90.12M P/S 3.40 EPS this Y 38.97% Inst Trans -4.28% Short Ratio 1.21 Perf Half Y 256.08%
Book/sh 0.68 P/B 2.44 EPS next Y 19.49% ROA -49.80% Short Interest 3.11M Perf Year 120.37%
Cash/sh 1.65 P/C 1.01 EPS next 5Y -7.30% ROE -110.95% 52W Range 0.41 - 1.75 Perf YTD 195.58%
Dividend Est. - P/FCF - EPS past 5Y - ROI -80.69% 52W High -4.57% Beta 0.72
Dividend TTM - Quick Ratio 6.14 Sales past 5Y -20.42% Gross Margin 62.53% 52W Low 304.75% ATR (14) 0.15
Dividend Ex-Date - Current Ratio 6.45 EPS Y/Y TTM 26.08% Oper. Margin -150.05% RSI (14) 69.11 Volatility 10.80% 12.80%
Employees 137 Debt/Eq 1.76 Sales Y/Y TTM -2.10% Profit Margin -306.31% Recom 3.00 Target Price 3.00
Option/Short Yes / Yes LT Debt/Eq 1.61 EPS Q/Q 30.53% Payout - Rel Volume 0.96 Prev Close 1.65
Sales Surprise 11.47% EPS Surprise -4.56% Sales Q/Q 8.45% Earnings Mar 04 AMC Avg Volume 2.58M Price 1.67
SMA20 18.95% SMA50 56.00% SMA200 138.33% Trades
Volume 2,475,085 Change 1.21%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-20-23 Resumed JP Morgan
Underweight
Nov-09-23 Upgrade TD Cowen
Market Perform → Outperform
May-10-23 Upgrade Jefferies
Underperform → Hold
$1.50 → $1
Feb-24-23 Downgrade Jefferies
Hold → Underperform
$3.20 → $1.50
Aug-08-22 Downgrade JP Morgan
Neutral → Underweight
May-31-22 Resumed Jefferies
Hold
$12 → $4
Apr-18-22 Downgrade Goldman
Neutral → Sell
$3
Mar-15-22 Downgrade Mizuho
Buy → Neutral
$35 → $8
Mar-15-22 Downgrade Cowen
Outperform → Market Perform
Mar-14-22 Downgrade William Blair
Outperform → Mkt Perform
Mar-14-22 Downgrade Stifel
Buy → Hold
$24 → $5
Mar-14-22 Downgrade BTIG Research
Buy → Neutral
Mar-14-22 Downgrade BofA Securities
Neutral → Underperform
$18 → $6
Mar-09-22 Upgrade Oppenheimer
Perform → Outperform
$21
Nov-08-21 Upgrade The Benchmark Company
Hold → Buy
$20
Sep-10-21 Initiated BofA Securities
Neutral
$18
Jun-28-21 Upgrade Stifel
Hold → Buy
$22 → $24
May-18-21 Resumed Goldman
Neutral
$24
Feb-22-21 Downgrade The Benchmark Company
Buy → Hold
Jan-06-21 Initiated Stifel
Hold
$18
Show Previous Ratings
May-02-24 06:00PM
Apr-03-24 11:30AM
Mar-25-24 10:00AM
Mar-22-24 02:00PM
Mar-06-24 12:33PM
10:07AM
Loading…
Mar-05-24 10:07AM
09:13AM
09:00AM
07:19AM
(Thomson Reuters StreetEvents)
Mar-04-24 05:30PM
04:51PM
04:42PM
(Associated Press Finance)
04:15PM
08:30AM
Feb-27-24 06:00PM
06:00PM
Loading…
Feb-26-24 06:00PM
Feb-20-24 10:00AM
Jan-03-24 06:00PM
Dec-11-23 06:00PM
Dec-07-23 11:31AM
Nov-09-23 08:39AM
Nov-08-23 11:47AM
Nov-07-23 05:28PM
(Associated Press Finance)
04:15PM
Oct-31-23 06:00PM
Oct-26-23 10:02AM
Oct-23-23 10:08AM
Oct-13-23 08:30AM
Oct-02-23 09:00AM
Sep-27-23 09:00AM
07:54AM
Loading…
Sep-14-23 07:54AM
Sep-13-23 09:00AM
Sep-07-23 11:31AM
Sep-06-23 06:00PM
Aug-17-23 07:02PM
Aug-09-23 09:25AM
Aug-08-23 05:30PM
04:23PM
04:15PM
11:08AM
(American City Business Journals)
Aug-07-23 10:23AM
06:30AM
Aug-01-23 06:00PM
Jul-24-23 03:48AM
Jul-16-23 08:49AM
Jun-12-23 06:00PM
Jun-08-23 12:55PM
11:31AM
May-10-23 11:28AM
09:16AM
May-09-23 06:45PM
05:41PM
04:15PM
May-08-23 09:29AM
May-04-23 10:00AM
May-02-23 10:01AM
Apr-27-23 08:30AM
Apr-19-23 08:38AM
Apr-17-23 05:00PM
Apr-16-23 06:30AM
Apr-13-23 10:59AM
Apr-11-23 08:57AM
Apr-10-23 10:07AM
Apr-02-23 08:27AM
Mar-30-23 11:30AM
Mar-29-23 05:44PM
Mar-24-23 12:00PM
Mar-22-23 09:35AM
Mar-14-23 03:43AM
Feb-28-23 05:15PM
Feb-24-23 10:23AM
07:29AM
Feb-23-23 06:20PM
05:24PM
04:30PM
Jan-09-23 09:04AM
Jan-04-23 09:00AM
Dec-12-22 10:05AM
Dec-05-22 08:00AM
Nov-10-22 09:05AM
07:58AM
Nov-09-22 09:00AM
Nov-04-22 12:35PM
Nov-03-22 06:35PM
Oct-28-22 10:00AM
Oct-27-22 10:02AM
Oct-25-22 06:00PM
Oct-24-22 07:55AM
Oct-11-22 05:13PM
(American City Business Journals)
Oct-07-22 03:42PM
(American City Business Journals)
11:21AM
Sep-07-22 01:15AM
Aug-21-22 09:57AM
Aug-16-22 08:30AM
Aug-05-22 12:11PM
Aug-04-22 06:15PM
04:15PM
Jul-26-22 06:00PM
Jul-14-22 06:01AM
Jul-01-22 06:30AM
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ROBIN HOWARD W President & CEO Feb 20 '24 Sale 0.68 20,033 13,622 879,889 Feb 22 08:16 PM Zalevsky Jonathan Chief R&D Officer Feb 20 '24 Sale 0.68 9,014 6,130 265,025 Feb 22 08:19 PM Wilson Mark Andrew Chief Legal Officer Feb 20 '24 Sale 0.68 7,606 5,172 236,674 Feb 22 08:17 PM ROBIN HOWARD W President & CEO Nov 17 '23 Sale 0.49 19,877 9,740 899,922 Nov 20 08:58 PM Zalevsky Jonathan Chief R&D Officer Nov 17 '23 Sale 0.49 9,646 4,727 274,039 Nov 20 09:02 PM Wilson Mark Andrew Chief Legal Officer Nov 17 '23 Sale 0.49 7,179 3,518 243,780 Nov 20 09:00 PM Curet Myriam Director Sep 18 '23 Sale 0.69 4,359 3,008 27,418 Sep 20 08:09 PM Ajer Jeffrey Robert Director Sep 18 '23 Sale 0.69 4,359 3,008 34,153 Sep 20 08:06 PM ROBIN HOWARD W President & CEO Aug 16 '23 Sale 0.78 19,998 15,598 919,799 Aug 17 08:06 PM Zalevsky Jonathan Chief R&D Officer Aug 16 '23 Sale 0.78 9,703 7,568 283,685 Aug 17 08:08 PM Wilson Mark Andrew Chief Legal Officer Aug 16 '23 Sale 0.78 7,221 5,632 250,959 Aug 17 08:07 PM WHITFIELD ROY A Director Jun 14 '23 Sale 0.57 30,000 17,100 216,250 Jun 15 06:26 PM ROBIN HOWARD W President & CEO May 16 '23 Sale 0.72 20,361 14,660 939,797 May 17 08:27 PM Zalevsky Jonathan Chief R&D Officer May 16 '23 Sale 0.72 9,791 7,050 293,388 May 17 08:29 PM Wilson Mark Andrew Chief Legal Officer May 16 '23 Sale 0.72 7,543 5,431 257,680 May 17 08:28 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
